Eris Lifesciences Limited Q4 FY25 Revenue at INR 705 Crore, up 28% YoY
Mumbai, May 19, 2025: Eris Lifesciences Limited, a leading Indian branded formulations manufacturing company, today announced its earnings for the fourth quarter and full year FY25.
Consolidated Financial Highlights:
| Particulars (INR crore) | Q4FY25 | Q4FY24 | YoY(%) | FY25 | FY24 | YoY(%) | |||||||
| Revenue | 705 | 551 | 28.0% | 2,894 | 2,009 | 44.0% | |||||||
| Gross Profit | 535 | 433 | 23.6% | 2,180 | 1,629 | 33.8% | |||||||
| EBITDA | 252 | 148 | 70.0% | 1,017 | 675 | 50.7% | |||||||
| EBITDA Margin | 35.8% | 26.9% | 886 bps | 35.2% | 33.6% | 161 bps | |||||||
| PAT | 102 | 80 | 28.3% | 375 | 397 | -5.7% | |||||||
| PAT Margin | 14.5% | 14.5% | 0 bps | 12.9% | 19.8% | -687 bps |
Commenting on the results, Mr. Amit Bakshi, Chairman & Managing Director of Eris Lifesciences Ltd., said,“Our Branded Formulations business has delivered a 10% organic growth in Q4. Our Diabesity strategy is progressing in line with our expectations and we have created an exciting pipeline in Insulins, Analogues and GLPs. We will take the lead in ensuring continued supply of life-saving insulins to patients across the country following the impending exit of the innovator from the RHI Penfill market. With our FY23 and FY24 investments fully integrated and growth-ready, we look forward to an exciting phase of secular growth over the next 3 years.”
Mr. Krishnakumar Vaidyanathan, Executive Director & Chief Operating Officeradded,“We have realised significant operating margin improvements in our DBF business due to synergies from business integration and rapid progress in insourcing of manufacturing, including the start of insulin production from our Bhopal facility. We have made significant investments in Swiss Parenterals to create new revenue streams, the full potential of which will start getting realised from FY27. We are entering a 3-year period of secular organic growth with significant inflection expected in our EPS and ROCE trajectories.”
Q4FY25 and FY25 – Financial Highlights
- Revenue of Q4 FY 25 grew by 28% YoY to INR 705 Cr and FY 25 grew by 44% YoY to INR 2,894 Cr
- EBITDA for Q4 FY 25 is INR 252 Cr, with 36% EBITDA margin and FY 25 is INR 1,017 Cr with 35% EBITDA margin
- PAT for Q4 FY 25 is INR 102 Cr with 14% PAT margin and FY 25 is INR 375 Cr with 13% PAT margin
- Operating Cash flows are 111% of EBITDA in Q4 and 105% of EBITDA in FY 25
- Net Debt as on 31 March is ~INR 2,222 Cr
FY25 – Business Highlights
- Organic Domestic Branded Formulations business grew by 9% yoy
- Domestic Branded Formulations segment revenue grew by 32% yoy and EBITDA margin grew by 207 bps
- 15 out of Top-25 mother brands ranks among Top-5 in their respective markets with revenues of 5 mother brands above INR 100 Crs.
Bhumika Lenka
About Author
